- Home
- RFAI vs NOTV Comparison
RFAI vs NOTV Comparison
Compare RFAI & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- NOTV
- Stock Information
- Founded
- RFAI 2024
- NOTV 1974
- Country
- RFAI Singapore
- NOTV United States
- Employees
- RFAI N/A
- NOTV N/A
- Industry
- RFAI
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- RFAI
- NOTV Health Care
- Exchange
- RFAI NYSE
- NOTV Nasdaq
- Market Cap
- RFAI 153.0M
- NOTV 126.3M
- IPO Year
- RFAI 2024
- NOTV 1997
- Fundamental
- Price
- RFAI $10.25
- NOTV $4.27
- Analyst Decision
- RFAI
- NOTV Strong Buy
- Analyst Count
- RFAI 0
- NOTV 3
- Target Price
- RFAI N/A
- NOTV $5.92
- AVG Volume (30 Days)
- RFAI 19.6K
- NOTV 1.2M
- Earning Date
- RFAI 01-01-0001
- NOTV 02-05-2025
- Dividend Yield
- RFAI N/A
- NOTV N/A
- EPS Growth
- RFAI N/A
- NOTV N/A
- EPS
- RFAI N/A
- NOTV N/A
- Revenue
- RFAI N/A
- NOTV $490,739,000.00
- Revenue This Year
- RFAI N/A
- NOTV $7.14
- Revenue Next Year
- RFAI N/A
- NOTV $5.73
- P/E Ratio
- RFAI N/A
- NOTV N/A
- Revenue Growth
- RFAI N/A
- NOTV N/A
- 52 Week Low
- RFAI $10.25
- NOTV $1.23
- 52 Week High
- RFAI $10.27
- NOTV $11.42
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- NOTV 49.19
- Support Level
- RFAI N/A
- NOTV $3.87
- Resistance Level
- RFAI N/A
- NOTV $4.67
- Average True Range (ATR)
- RFAI 0.00
- NOTV 0.54
- MACD
- RFAI 0.00
- NOTV -0.10
- Stochastic Oscillator
- RFAI 0.00
- NOTV 22.22
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.